Nonspecific Orbital Inflammation (Idiopathic orbital inflammation, Orbital inflammatory syndrome, Orbital pseudotumor)

From EyeWiki

Jump to: navigation, search
Nonspecific Orbital Inflammation (Idiopathic orbital inflammation, Orbital inflammatory syndrome, Orbital pseudotumor)
Classification and external resources

Axial CT of NSOI of extraocular muscles (orbital myositis)

ICD-10 H05.1
ICD-9 376.11
MeSH D016727


Nonspecific orbital inflammation (NSOI), also known as orbital inflammatory pseudotumor, idiopathic orbital inflammation and orbital inflammatory syndrome is the most common cause of painful orbital mass in adults.[1] NSOI can be localized or diffuse. When localized, inflammation can affect the extraocular muscles (orbital myositis), lacrimal gland (dacryoadenitis), sclera (scleritis), uvea (uveitis), and the superior orbital fissure and cavernous sinus (Tolosa-Hunt syndrome). When diffuse, NSOI may diffusely involve the orbital fatty tissues. NSOI is the third most common orbital disease after thyroid eye disease and orbital lymphoma.[1] NSOI can both radiologically and clinically mimic a malignant process. Therefore, it is a diagnosis of exclusion, only after all other causes of inflammation have been eliminated. Treatment options are varied and can include surgery, steroids, chemotherapeutic agents and irradiation.[2]


Contents

Disease Entity

International Classification of Disease (ICD)

ICD-9-CM 376.11 Orbital granuloma
ICD-10-CM H05.11 Granuloma of orbit


History

Nonspecific orbital inflammation was first described in 1905 by Birch-Hirschfeld.[3] It was named as inflammatory pseudotumor in 1954 by Umiker et al.[4] because of its propensity to mimic a malignant process. Since that time NSOI has been called many different names including plasma cell granuloma, histiocytoma, xanthoma, solitary mast granuloma, fibrous xanthoma and others.[2] Presently, Nonspecific orbital inflammation and orbital inflammatory pseudotumor can be used interchangeably.


Definition

NSOI is a benign inflammatory process of the orbit characterized by a polymorphous lymphoid infiltrate with varying degrees of fibrosis, without a known local or systemic cause.[5]


Incidence

The true incidence of NSOI is difficult to assess given the wide range of manifestation and lack of universally accepted definition. NSOI has been shown to account for up to 6.3% of orbital disorders.[6] Pediatric cases account for about 6-17% of the total incidence.[7],[8]


Frequency of NSOI subtypes

Swamy et al.[9] reviewed 24 patients with biopsy proven NSOI and found that the lacrimal gland was affected 54.2% of the time (13/24), extraocular muscles 50.0% (12/24), orbital fat 75.0% (18/24), sclera 4.2% (1/24), optic nerve 20.8% (5/24) and other 8.3% (2/27). Yuen and Rubin[10] reviewed 65 patients with diagnosis of NSOI and found that the lacrimal gland was affected 32% (21/65), extraocular muscles 29% (19/65), lacrimal gland and extraocular muscles 8% (5/65), orbital apex 9% (6/65), and other 22% (14/65).


Histopathology

The histopathologic spectrum of NSOI is typically nondiagnostic secondary to the wide range of presentation ranging from the typical diffuse polymorphous infiltrate to lymphoid, granulomatous, sclerosing, eosinophilic or vasculitic inflammation.[11] Granulomatous NSOI is rare but has been reported.[12]  In the early stages the polymorphous inflammatory response predominates; in later stages fibrosis is a predominant feature. Fibrosis is often seen with interspersed lymphoid follicles with germinal centers and may replace orbital fat and encase extraocular muscles and the optic nerve.[13]  Several histopathologic classification schemes have been proposed; Blodi and Gass presented 9 subdivisions[7][8], Reese presented 5 subdivisions[14] and Farrow proposed 2 classes.[15] However, to date, no one classification scheme has been universally accepted. This is likely due to the lack of clear-cut differences among the histopathological types.


Pathophysiology

The etiology and pathogenesis of NSOI is currently unknown. Both infectious and immune-mediate etiologies have been implicated. Purcell and Taulbee[16] reported a case of new onset orbital myositis within two weeks after confirmed streptococcal pharyngitis. Others have reported association with Lyme disease[17] as well as herpes zoster ophthalmicus.[18][19] Wirostko et al.[20] has suggested that the parasitisation of orbital leukocytes by organisms that resemble Mollicutes (MLO) may be the underlying mechanism of some forms of vasculitic NSOI.


NSOI has also been observed in association with a variety or rheumatologic conditions including Crohn's disease, systemic lupus erythematous, rheumatoid arthritis, myasthenia gravis, and ankylosing spondylitis.[11][21][22][23][24] Mombaerts et al.[25] found in their series that 10% of their patients with NSOI also had a concurrent autoimmune disease. In another study by Sobrin et al.[26], 21 of 27 patients that were treated with infliximab for ocular inflammation were found to have coincidental rheumatologic disease. Atabay et al.[27] reported that circulating antibodies against eye muscle antigens are present in patients with orbital myositis. They found autoantibodies active against eye muscle membrane proteins of 55 and 64 kilodaltons which were seen in 63% of the orbital myositis patients compared with 16-20% in healthy patients. It has been proposed that this autoimmunity may be the ocular mechanism for some forms of orbital myositis. However, antibodies to this protein have also been seen in thyroid orbitopathy.[27] Additionally, the typical unilateral presentation of NSOI argues against this type of autoimmunity as being the primary mechanism of NSOI.


The sclerosing form of NSOI has been shown to be similar to fibroproliferative disorders with Levine et al.[28] describing a patient with bilateral sclerosing orbital inflammation and retroperitoneal fibrosis. Rootman et al.[29] proposed that in sclerosing NSOI, fibroproliferation occurs via production of immune-mediated fibrogenic cytokines. Histologically, sclerosing NSOI consists of dense fibrotic tissue with infiltrates consisting of predominantly T-cells.[30] Recent evidence has suggested that Immunoglobulin G4 positive plasmacytic infiltrates can be markers of sclerosing NSOI.[31]


Mottow-Lippe et al.[32] suggest that trauma may cause increased vascular permeability resulting in release of antigenic substances which in turn incite an inflammatory cascade. They propose that the variable nature and multi-focality of NSOI can be explained by the network of connective tissue and capillaries delivering antigenic agents to a variety of orbital structures. Wladis et al.[33] performed quantitative cytokine assays for 9 different molecules and noted that six cytokines were significantly elevated in NSOI (interleukin-2, -8, -10, -12, gamma interferon, and tumor necrosis factor alpha). An animal model has been proposed however more complete models are needed to better understand NSOI pathophysiology and optimum treatment protocol.[34] Differentiation of NSOI from lymphoid tumors can be accomplished by investigating clonality of lymphocytes, polyclonal (NSOI) and monoclonal (lymphoma).[13] Interference of CD20, CD25 and Toll-like receptors may provide the basis for future therapies.[13][35] An immune-mediated pathophysiology is strongly suggested by increased cytokines and favorable, rapid responses of inflammation to systemic corticosteroids and other immunosuppressive agents. These therapies will be discussed further in the management section.


Diagnosis

Clinical Presentation

All patients with suspected NSOI require a full ophthalmic assessment/workup. NSOI is typically characterized by the abrupt onset of pain, proptosis and other inflammatory signs such as swelling and erythema. Unilateral presentation is more typical but bilateral presentations are not uncommon.[10] Pediatric NSOI differs from the adult presentation and is more commonly characterized by bilateral manifestation, uveitis, disc edema and eosinophilia.[36] Pain is the most common symptom in adult NSOI and occurs 58-69% of the time followed by diplopia (31-38%).[36][37] Periorbital edema/swelling is the most common sign and occurs 75-79.2% of the time (figure) followed by proptosis (32-62.5%), EOM restriction (54.2%) red eye (48%), chemosis (29%), decreased vision (20.8%), and ptosis (16.7%).34-35 Therefore, physical examination of patients with suspected NSOI involves lid assessment (retraction/lid lag/lagophthalmos), orbital assessment (proptosis), extraocular muscles (restriction), globe (injection/chemosis), and optic nerve function (visual acuity/color plates/relative afferent pupillary defect). Because of the association between rheumatologic disease and NSOI the typical laboratory work-up for suspected NSOI should include a complete blood count, basic metabolic panel, thyroid function studies, erythrocyte sedimentation rate, antinuclear antibodies, antineutrophil cytoplasmic antibodies, angiotensin-converting enzyme level, rapid plasma reagin test, and rheumatoid factor.[11]


Figure 1: Dense upper eyelid edema and swelling in a patient with lacrimal gland NSOI, Courtesy of Professor M Chua


Imaging

Evaluation of NSOI will frequently involve high-resolution computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI). CT is the preferred method because of its good inherent contrast of orbital fat, muscle, bony structures, and air in the adjacent paranasal sinuses.[2] MRI is preferred in demonstrating soft tissue changes in the region of the cavernous sinus/superior orbital fissure due to beam hardening and bone streak artifacts seen in CT.[38] Kapur et al.[39] have noted different intensities diffusion-weighted imaging (DWI) between NSOI, orbital cellulitis and orbital lymphoid. Therefore, DWI may help differentiate these entities.[39] Radiologic findings allow subtypes of NSOI to be more precisely classified and are as follows:[1][10][37][40][41][42][43]


Lacrimal gland

The lacrimal gland will appear diffusely enlarged with overall preservation of its shape. There may be blurring at the gland margin with marked expansion along the lateral orbital wall and lateral rectus muscle (Figure 2).

Figure 2: Diffusely enlarged right lacrimal gland with blurring of gland margin. Courtesy of Professor M Chua

Figure 2: Diffusely enlarged right lacrimal gland with blurring of gland margin. Courtesy of Professor M Chua

Extraocular muscles

Enlargement of the extraocular muscles will be seen (single or multiple). Unilateral single muscle inflammation with tendon involvement is most common. The most frequently involved muscle is the medial rectus followed by the superior rectus, lateral rectus and inferior rectus. The tendon may also enlarge and together with enlargement of the muscle bundle lead to a tubular configuration (Figure 3). There may be infiltrates throughout the orbital fat bordering the muscle, blurring the margin of the muscle.

Figure 3: CT image of bilateral medial and lateral rectus tubular-like enlargement with tendon involvement. Courtesy of Z.X. Ding
Figure 3: CT image of bilateral medial and lateral rectus tubular-like enlargement with tendon involvement. Courtesy of Z.X. Ding


Optic nerve

Inflammatory tissues surrounding an unenhanced optic nerve may demonstrate the classical, "tramline" sign (Figure 4). There may be streaky densities in the contiguous orbital fat.

Figure 4: CT image of optic nerve involvement with sheath enhancement ("tramline" sign) (asterisks), white arrow showing right lacrimal gland enlargement. Courtesy of Z.X. Ding
Figure 4: CT image of optic nerve involvement with sheath enhancement ("tramline" sign) (asterisks), white arrow showing right lacrimal gland enlargement. Courtesy of Z.X. Ding

 

Sclera, episclera, Tenon's capsule, and uvea:

Imaging will demonstrate non-specific thickening of structures. Blurring of the sclera margin may be seen (Figure 5).

Figure 5: CT image showing thickening and blurring of left eye uveoscleral (asterisks). Courtesy of Z.X. Ding

Figure 5: CT image showing thickening and blurring of left eye uveoscleral (asterisks). Courtesy of Z.X. Ding


Orbital fat

Diffuse infiltration and inflammation will be seen in the orbital fat and may envelop the globe and optic nerve sheath complex (Figure 6).

Figure 6: CT image showing enhancement of orbital fat (asterisks). Courtesy of Z.X. Ding
Figure 6: CT image showing enhancement of orbital fat (asterisks). Courtesy of Z.X. Ding


Orbital apex, cavernous sinus and intracranial involvement:

There may be compression, obliteration or displacement of the optic nerve. The cavernous sinus (Figure 7) and middle cranial fossa are the two most common locations for intracranial extension of NSOI. Intracranial involvement can feature abnormal soft tissue in the superior orbital fissure, expansion of the ipsilateral cavernous sinus and thickening of the meninges contiguous with the orbital inflammation.

Figure 7: MRI, fat-saturated, T1-weighted image with white arrows showing extension into the cavernous sinus. Courtesy of Z.X. Ding
Figure 7: MRI, fat-saturated, T1-weighted image with white arrows showing extension into the cavernous sinus. Courtesy of Z.X. Ding

 

Biopsy

Biopsy for NSOI is not usually indicated. There may be not be a distinct mass to biopsy or the lesion may be unapproachable and response to therapy can be confirmatory.[44] Biopsy may be considered if there are progressive neurologic deficits, lack of steroid responsiveness and persistent imaging abnormalities. In their 10-year retrospective review of NSOI, Yuen and Rubin[10] noted that biopsies were performed in 19 or 29% of NSOI patients. Fourteen of those biopsies revealed non-specific inflammatory pattern and the remaining showed a sclerosing pattern with dense fibrosis. Approach to biopsy varies greatly depending on location. Direct skin incision (Figure 8) or orbitotomy is required for tissue biopsy. Ultrasound or CT guided fine needle aspiration (FNA) has also been shown to be a useful tool in evaluating patients with suspected NSOI.[45][46]

Figure 8: Showing whitish infiltration of the lacrimal gland on direct upper eyelid incision, Courtesy of Professor M Chua
Figure 8: Showing whitish infiltration of the lacrimal gland on direct upper eyelid incision, Courtesy of Professor M Chua


Differential Diagnosis

There are many processes that can mimic NSOI. The most common orbital processes that present with similar clinical pictures as NSOI are thyroid eye disease and orbital cellulitis.9 Thyroid eye disease is the most common cause of orbital inflammation in adults and has been found to account for nearly 60% of cases of orbital inflammation in the 21-60 year old age group.[47] Orbital cellulitis risk factors include history of sinusitis, dental work/disease, or trauma.[48][49] Table 1 outlines common differential diagnosis for NSOI.

Table 1: Differential Diagnosis of Orbital Inflammation
Table 1: Differential Diagnosis of Orbital Inflammation[11][37][44][49][50][51][52][53][54][55][56]


Management

Observation

Observation for NSOI for mild cases of inflammation may be acceptable. Swamy et al.[9] reviewed the treatment of 24 NSOI patients with a minimum 6 month follow-up and found that 20.8% (5/24) that were treated with observation alone had maintained remission. If there is no clinical resolution or worsening of symptoms then additional therapy is indicated.


Non-steroidal anti-inflammatory drugs (NSAIDs)

NSAIDs, such as ibuprofen, have been used in mild cases of NSOI. There has been no formal study evaluating the use of NSAIDS in NSOI. Mannor et al.[57] reported that NSAIDs could be used up to 3 weeks as long as clinical resolution was being observed, with steroids reserved for refractory cases. The side effects to NSAIDs are dose-dependent with an estimated 10-20% of NSAID patients experiencing dyspepsia which can be reduced through suppressing acid production, via a proton pump inhibitor, e.g. omeprazole or esomeprazole.[58]


Corticosteroids

Systemic corticosteroids are generally considered mainstay therapy for NSOI.[11][44] Typically, response to steroids is rapid with a dramatic improvement in all symptoms and findings. In their review of 65 NSOI patients, Yuen and Ruben[10] found that 69% were treated with steroids alone, 12% with steroids and radiation therapy and 9% with steroids and NSAIDs. Yuen and Ruben[10] also noted that 24 patients had treatment failures with steroid dependence and steroid intolerance occurring 33% and 13% of the time, respectively. In an earlier study, Mombaerts et al.[59] found that 78% of patients with NSOI had a positive initial response to steroids but only 37% were cured with 52% having disease recurrence. In the same study Mombaerts et al.[59], noted that optic neuropathy caused by NSOI had a excellent 95% response rate. It has been shown that the sclerosing and vasculitic subtypes of NSOI have poorer responses to steroid treatment.[29][60] Treatment doses can differ in range but are generally 1.0-1.5 mg/kg or 50-100 mg/day for 1-2 weeks followed by slow taper for 5-8 weeks. If there is a reoccurrence of NSOI as steroids are tapered, dosage may need to be increased until NSOI is under control again or alternative treatments may be considered. Bijlsma et al.[61] compared intravenous methylprednisolone (IVMP) plus oral prednisone with oral prednisone alone and found that IVMP did not result in a shorter duration of prednisone therapy or difference in symptom-free outcome or recurrence rate. With long-term use of systemic corticosteroids bone density must be monitored. Adverse side effects include mood or weight changes, hyperglycemia, GI distress and accelerated loss of bone density.[62]


Radiation therapy

Radiation therapy can be used in the treatment of NSOI. It is generally used when NSOI is found to be resistant to or intolerant to corticosteroid therapy.[29] The results of radiotherapy have been reported to have success rates ranging between 50-75%.[63][64] Other authors have published greater long-term control to ranging from 66%-100% success after a total dosage of 2000 cGy.[63][65] In there review of 24 NSOI patients treated with radiation therapy, Lanciano et al.[63] found that 87% of patients had soft tissue swelling improvement, 82% with improvement in proptosis, 78% with improved ocular motility restriction and 75% had decreased pain. Kennerdell et al.[66] showed benefit at doses of 2500 to 3000 cGy over ten days, Sergott et al.[67] at doses of 1000 to 2000 cGy over 10-15 days and Orcutt et al.[64] at 2500 cGy over 15 days. Response may vary pending the subtype of NSOI. It has been demonstrated that myositis subtype may respond well,[68] whereas sclerosing or granulomatous variants may respond poorly.[29] The vasculitic subtype has been shown to be successfully treated with radiation therapy,[60] while some have noted poor response.[60][59] At approximately 2000 cGy of irradiation, the lens is at risk for developing a cataract.[10] Other side effects such as dry eye, retinopathy and optic neuropathy are typically observe with radiation doses greater than 3000 to 4000 cGy.[10]


Calcineurin inhibitors:

Cyclosporine-A (CsA)

CsA is an im
munosupressent that acts on T-lymphocytes. It inhibits synthesis T-cell growth cytokines, IL-2 and IFN-γ.[69] A few studies have shown that cyclosporine can be efficacious in diabetic NSOI patients who cannot tolerate steroids.[2] Diaz-Llopis and Menezo[70] recommend treating NSOI with 5mg/kg/day then tapering to 2mg/kg/day over ten months. Zacharopoulos et al.[71] treated a patient using 4mg/kg/day for 6 weeks and this patient remained symptom free for 5 years without any medication. Topical .05% CsA (Restasis) in combination with topical dexamethasone .1% eye drops have also been shown to be useful in one case report of a 35-year old women who was intolerant to systemic CsA.[72] For immunosuppression, Hemady et al.,[69] recommend cyclosporine trough levels between .1 and .4 mg/ml. Cyclosporine has numerous side effects. It is imperative to monitor renal function as levels greater than 300 to 350 ng/ml can cause permanent renal damage.[71][73] Other complications include hypertension, tremor, hirsutism, hyperlipedemia, transient liver dysfunction and gingival hyperplasia.[74]  CsA has been implicated in secondary malignancies however a meta-analysis review by Buell and Koo[75] indicated that there was no statistically significant increased risk of malignancy with CsA use.


Tacrolimus

Tacrolimus (Fk506) is very similar to cyclosporine but is approximately 10 times more potent.[76] Tacrolimus has been shown to be useful for ocular immunosupression,[77][78] but literature regarding treatment of NSOI has been very limited. Winn and Rootman[79] reviewed all cases of sclerosing orbital disease from 1976 to 2008 and found one patient who developed recurrence while on tacrolimus and another with poor response to oral steroids but good response to radiation therapy combined with tacrolimus. Tacrolimus side effects can be severe and range greatly from infection, hypertension, liver and nephrotoxicity, metabolic abnormalities and lung damage.


Antiproliferative drugs (Cytotoxic):

Azathioprine

Azathioprine is a mercaptopurine analong which inhibits purine metabolism enzymes. There are only case reports regarding azathioprine treatment for NSOI. Garrity et al.[60] noted that azathioprine was ineffective in a patient with vasculitic NSOI, however, Rootman et al.[29] found azathioprine useful in one patient in conjunction with systemic corticosteroids. Azathioprine can cause bone marrow suppression, skin rashes, liver dysfunction, nausea and vomiting and oncogenesis (non-hodgkin’s lymphoma, squamous cell carcinomas and mesenchymal tumors).[76][80][81]


Chlorambucil

Chlorambucil is a chemotherapy drug that is used mostly in the treatment of chronic lymphocytic leukemia.[82] Only one case report documents use of chlorambucil in NSOI. Paris et al.[83] reported that pulsed therapy of chlorambucil combined with prednisone was effective in NSOI refractive to both corticosteroids and radiation therapy. As with other alkylating agents bone marrow suppression and subsequent anemia, neutropenia and thrombocytopenia can occur.[82]


Cyclophosphamide

Cyclophosphamide is a B-cell cytotoxic alkylating agent.[74] There are only limited case reports of cyclophosphamide used in NSOI. Paris et al.[83] reported effectiveness with pulsed cyclophosphamide combined with prednisone. Other cases reports have demonstrated durable anti-inflammatory effect for up to 7 years.[60][83][84] In cases of sclerosing NSOI, Winn and Rootman[79] noted one patient with improvement with cyclophosphamide but with recurrence 6 years later, another patient with good response to cyclophosphamide, one that developed recurrence but achieved control with cyclophosphamide, and one that appeared stable with cyclophosphamide plus colchicine. Adverse drug reactions include nausea and vomiting, bone marrow suppression, gastrointestinal distress, diarrhea, alopecia and lethargy.[83][84] Hemorrhagic cystitis can also occur but is prevented by fluid intake and mesna.[85] A long-term complication can be the development of transitional cell carcinoma of the bladder.[85]


Leflunomide

Leflunomide is a pyrimidine synthesis inhibitor which has anti-inflammatory, immunosuppresive and antiproliferative properties.[86] It has been shown to be effective in the treatment of severe psoriatic and rheumatoid arthritis.[87][88] Only one case report has documented use of leflunomide in NSOI. Marino and Wason[86] reported the successful treatment of a 25 year old woman with leflunomide 40mg daily after discontinuation of methotrexate resulted in recurrence. After one week the patient's leflunomide dose was reduced to 20mg daily and she remained free of symptoms and without adverse effects for 5 months. Leflunomide's most serious adverse effect can be liver damage. More common side effects include diarrhea, alopecia and rash.[89]


Methotrexate

Methotrexate is an inhibitor of dihydrofolate reductase, an enzyme needed in folic acid synthesis. This results in suppression of both T-cell and B-cell functions. Methotrexate is also known to enhance the release of adenosine, which has potent anti-inflammatory effects.[62] Methotrexate has a long history of success in the treatment of rheumatoid arthritis.[44] For ocular immunosupression Hemady et al[69] recommend 10 to 25 mg divided over 36 to 48 hours every 1 to 4 weeks. Smith and Rosenbaum[90] reported treating seven NSOI patients with methotrexate ranging from 15 to 25 mg/week for periods of 4 weeks to 34 months. Of those seven patients 4 demonstrated clinical benefit, in one patient methotrexate was stopped due to side effects, in one there was no response, and 2 patients did not complete the 4 months trial for undisclosed reasons. Shah et al.[91] evaluated methotrexate use in NSOI at low doses of 12.5 mg/wk and reported 16 out of 22 patients that had a reduction of inflammatory activity. Fourteen of the 16 patients were able to taper or discontinue corticosteroid therapy and 5 patients had complete remission. Six patients did not response to methotrexate. Prominent side effects of methotrexate include gastrointestinal disturbances, arthralgias, liver abnormalities, alopecia, fatigue and headache.[11][62][74][76][90] Dietary supplements of folate, restriction of alcohol intake and parenteral administration of methotrexate can prevent these side effects.


Mycophenolate mofetil (MMF)

Mycophenolate mofetil is an antimetabolite with immunosuppressive activity. It has been shown to be effective in the treatment of uveitis, scleritis and mucus membrane pemphigoid.[92] Hatton et al.[93] reviewed of 4 NSOI patients treated with MMF and concurrent corticosteroids and 1 patient. Severe nausea developed in one patient and required discontinuation but the remaining 4 were found to complete resolution of inflammation, with median follow up of 8.5 months. The average dose of MMF was 2.2 g/d. A case report Patel et al.[94] describes one patient with sclerosing NSOI that poorly responded to 60 mg of daily prednisone and MMF was started resulting in drastic improvement in visual field and visual acuity. Most recently MMF has been shown to be effective in IgG4-related NSOI of the central nervous system.[95] MMF is generally well tolerated, with the most common side effect being gastrointestinal disturbances, nausea, increased cholesterol and metabolic abnormalities.[94][93] To minimize these side effects dosing can be started at 500mg/day and slowly increased.[94]


Cytokine/protein specific biologic agents:

Abatacept

Abatacept is a soluble, fully human, recombinant fusion protein that selectively modulates that CD80/CD86:CD28 co-stimulatory signal for T-cell activation.[96] Abatacept has been reported to be effective in methotrexate-resistant active rheumatoid arthritis and refractory juvenile idiopathic arthritis (JIA) related uveitis.[97][98][99] There have been no reports regarding treatment of NSOI with Abatacept. The most common side effects may include headache, nasopharyngitis and nausea.[97]  The incidence of infection has been shown to be increased when compared to that of a placebo.[97] As this drug is administered as an infusion, infusion reactions may also occur.[97]


Adalimumab

Adalimumab is a recombinant IgG1 monoclonal antibody containing 100% human peptide sequences targeting tumor necrosis factor alpha (TNF-α). TNF-α is a cytokinic key factor in the inflammatory cascade. Adalimumab has been proven to be effective in adult patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.[100][101][102] Case series have documented benefit in patients with anterior uveitis, Behçet uveitis and pediatric uveitis.[101][103][104] Adams et al.[105] describe 2 patients with refractory, steroid-dependent, recurrent orbital myositis who both improved after adalimumab treatment without disease flare. As with any other immunosuppressive agent, the risk of infection is increased. Risk of lymphoma has been shown to be increased in patients with long-standing rheumatoid arthritis, a group already at increased risk for development of lymphoma.[106] In pooled analysis of four trials Injection site reactions with adalimumab occurred in about 20.9% of patients compared with 13.8% with placebo. Common site reactions including erythema, itching, hemorrhage and pain/swelling.[107] Chung et al.[108] have described cases of optic neuritis associated with adalimumab.


Daclizumab

Daclizumab is a recombinant monoclonal human-murine immunoglobulin that binds to IL-2 receptors inhibiting activation of lymphocytes.[109] Daclizumab was reported to be successful in the treatment of 10 patients with various types of uveitis, scleritis, ocular cicatricial pemphigoid, keratouveitis and birdshot chorioretinopathy.[110][111][26] Garcia-Pous et al.[112] reported benefit in a patient with chronic orbital myositis when daclizumab was used in combination with corticosteroids and cyclosporine. Daclizumab has been known to cause increased fatigue, increased rate of infection and dermatitis.[110][111][112][26]


Etanercept

Etanercept is a a dimeric fusion protein combining two TNF receptors linked to an Fc portion of an IgG1 which neutralizes TNF-α before it binds to its receptor. It can only neutralize soluble TNF-α. It is commonly use in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[113][114][115] The results of etanercept for eye related diseases have been mixed. In a randomized, double blind trial of 18 patient with ocular sarcoidosis there was found to be no therapeutic benefit over placebo.[116] A similar results was reported in the treatment of JIA uveitis.[90] The Wegener's Granulomatosis Etanercept Trial (WEGET) was a randomized, placebo-controlled trial where etanercept was evaluated for maintenance of remission in 180 patients. The study found that etanercept was ineffective, but also those treated with etanercept were found to have a higher risk of developing solid tumors in comparison with those treated with cyclophosphamide.[117] Paridaens et al.[118] reported 10 thyroid eye disease patients who benefited from subcutaneous injections of 25mg of etanercept with an improvement of clinical activity score by 60% and an ophthalmology index improvement of 24%. Side effects of etanercept include cytopenia, infections and injection site reactions. Paradoxically, there have been reports etanercept-associated uveitis, scleritis and orbital myositis.[119] Given these findings etanercept should be used cautiously when attempting to treat refractory NSOI.


Infliximab

Infliximab is a chimeric monoclonal antibody against TNF-α. As infliximab is one of the first specific agents to be directed against TNF-α, there has been more evidence regarding its use in variety of ocular disease. It has been so successful in Behçet's disease that it is becoming the treatment of choice for this disorder.[120][121] There has been increasing body of evidence that infliximab is a useful therapeutic option in NSOI. Garrity et al.[122] reported the treatment of 7 patients with chronic and refractory orbital myositis. Patients received a dosing schedule of 3 to 5 mg/kg (up to 10 mg/kg) given at weeks 0,2,and 6 with treatments every 4 to 8 weeks afterwards. It was noted that all 7 patients had a favorable response to treatment with no untoward effects after a mean follow-up of 15.7 months (range, 4 to 31 months). Miguel et al.[123] has reported two cases of steroid dependent NSOI who developed adverse effects from conventional steroid-sparing agents, in both cases symptoms had disappeared with infliximab with follow-up of at least 20 months. Sahlin et al.[124] described successful treatment of 1 patient with sclerosing NSOI with combination infliximab and methotrexate therapy. Wilson et al.[125] has reported success in the treatment in a pediatric patient with refractory bilateral NSOI and has remained symptom free and off corticosteroids 2 years since initial diagnosis Side effects include rash, headache, respiratory congestion, hypotension, development of autoantibodies and possible risk of lymphoma.[126][127][128] The incidence of autoantibody formation has been shown to be lessened with concomitant use of methotrexate.[126][127][129] Some have reported that infliximab is the biologic agent of choice, given its proven efficacy in NSOI and well studied profile regarding other inflammatory disorders.[74]


Rituximab

Rituximab is a chimeric mouse-human monoclonal antibody against the protein CD20, which is primarily found on B-cells as a cell-surface protein. Although ritixumab is a monoclonal antibody it tends to act more as a cytotoxic agent than other biologic agents.[74] On et al.[130] first reported the use of rituximab in the successful management of one patient with refractory NSOI in combination with CyberKnife radiosurgery with rituximab dosing at 375mg/m2 IV weekly for 4 weeks. Schafranksi[131] reported success with rituximab in one patient with NSOI refractory to azathioprine therapy, at dosing of two 1000-mg infusions on days 0 and 15. Lastly, Ibrahim et al.[132] has reported successful treatment one patient with rheumatoid arthritis who developed NSOI refractory to adalimumab with ritixumab dosing of 1000-mg infusions administered 2 weeks apart. The side effects of rituximab include infusion site reactions, rash, rigors, fever, headache, infection, and bronchospasm.[74][133]


Tocilizumab

Tocilizumab is an anti-interleukin-6 receptor antibody that has been shown to be effective in the treatment of systemic-onset juvenile idiopathic arthritis and rheumatoid arthritis.[134][135] A review of 392 patients with noninfectious anterior scleritis showed 1 patient with successful treatment of scleritis with Tocilizumab.[136] Tappeiner et al.[137] reported 3 patients with JIA-associated uveitis that were treated with tocilizumab. Two out of the three patients achieved inactivity of uveitis while 1 patient required increased in the osage of topical steroids. In all three patients arthritis improved. To date toclizumab has not been reported in treating NSOI. The most common side effects of tocilizumab include upper respiratory tract infections, nasopharyngitis, headache, hypertension, and transient elevation of serum liver enzyme levels.[138] More serious side effects include neutropenia, serious infection, and thrombocytopenia.[139]


Intravenous Immunoglobulin and Plasmapheresis

Both intravenous immunoglobulin (IVIG) and plasmapheresis act via removal of autoantibodies by neutralization and filtration, respectively.[76] However, the exact mechanism of action of IVIG in immune-mediated diseases remains unknown.[140] It has been suggested that IVIG may activate the inhibitory Fc receptor pathway.[141] In one study, Rosenbaum et al.[142] treated 10 patients with refractory bilateral uveitis with IVIG and observed sustained and substaintial benefit in 5 out of the 10 patients for over 11 months. Shambal et al.[143] treated 1 patient with refractory orbital myositis with .3 g/kg/weight for 3 days and considerable improvement was noted. Symon et al.[144] reported the successful treatment of resistant NSOI with a total dose of 2g/kg divided over 4 days as an 8-hour infusion with resolution of pain and proptosis. IVIG has also been used successfully in the thyroid eye disease.[145] There have been no case reports of the use of plasmapheresis in the treatment of NSOI. IVIG is associated with thromboembolism, aseptic meningitis and the risk of transmission of blood-borne infection.[140] Despite the promise, IVIG is a limited resource and, therefore, is an extremely costly therapy.  As a result its use should probably be limited to those who have failed virtually all other available treatments.[140]


Surgical Therapy

Surgical resection can be an effective form of treatment in NSOI refractory to treatment. However, lesions must be localized for best surgical outcome. For diffuse, fibrotic lesions or lesions near vital structures surgical resection may not be viable. In an eye with a confirmed diagnosis of NSOI that becomes blind and painful or is completely refractory to all treatments exenteration may be considered.[10]


Decision Tree

Step 1: If negative proceed to step 2
Step 1: If negative proceed to step 2
STEP 2

Step 2


Outcomes

Outcomes regarding NSOI differ in the literature given the variability in both disease presentation and treatment protocols. Retrospective data from academic centers may reflect an overall higher rate of corticosteroid failures than observed in the community as these centers will generally see more severe or recalcitrant disease.


Mombaerts et al.[59] found that 78% of patients with NSOI had a positive initial response to steroids but only 37% were cured with 52% having disease recurrence. Mombaerts et al.,[59] also noted that optic neuropathy caused by NSOI had a excellent 95% response rate. It has been shown that the sclerosing and vasculitic subtypes of NSOI have poorer responses to steroid treatment.[29][60] In 2002, Yuen and Ruben[10] reviewed 65 NSOI patients who were treated at the Massachusetts Eye and Ear Infirmary from January 1991 to April 2001. Treatment modalities used included steroids, steroids and radiation, steroids and NSAIDs, radiation and NSAIDs, NSAIDs alone, surgical debulking and observation only. Of the 65 patients 41 (63%) had treatment success and had complete symptom relief; whereas 24 (37%) represented treatment failures. Of the 24 treatment failure patients, 14 (58%) inflammation had returned after a period of quiescence. For 9 (38%) of the 24 patients, the disease was severe with unremitting inflammation. It is important to note that the use of alternative therapies for NSOI was not commonly used at the time of Yuen and Rubin’s review.


Five years after Yuen and Rubin, Swamy et al.[9] published treatment outcomes of 24 patients with biopsy proven NSOI. Therapeutic modalities included observation alone, antibiotics, oral corticosteroids, intravenous corticosteroids, adjunctive radiation therapy and systemic immunosuppressive drugs (methotrexate, azathioprine, mycophenolate, and ciclosporine). Of the 24 patients, 16 (67%) had complete resolution of symptoms, 4 (17%) had partial resolution and 4 (17%) had no improvement in their symptoms. In 2012 Pemberton and Fay[146] reviewed all published cases of sclerosing NSOI. Seventeen articles with 56 biopsy-proven sclerosing NSOI with documented outcomes were reviewed. There were 15 different treatment regimens including steroids, radiation therapy and immunomodulatory drugs. Regardless of treatment modality the overall response was good in 19 (34%) patients, partial in 24 (43%), and poor in 13 (23%).

Discussion

NSOI is diagnosis of exclusion and is highly variable. Given the variable nature of the disease and the emergence of immunosuppresive drugs many therapeutic regimens exist. Retrospective studies have demonstrated that patients on average have symptomatic improvement. It is generally agreed upon that steroids are the initial treatment of choice for moderate to severe NSOI. There has yet to be long-term prospective studies evaluating the most appropriate treatment protocol. Given the infrequency and variable presentation of the disease it is unlikely large scale prospective studies will be completed in the near future. Pemberton and Fay[146] propose the creation of a multidisciplinary consortium of clinical and research scientists to develop standardized clinical criteria and management for sclerosing NSOI. Such collaboration would likely be helpful for any NSOI subtype. In the future newer therapeutic modalities may become standard of care.


Additional Resources

1. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002590/
2. http://www.nlm.nih.gov/medlineplus/ency/article/001623.htm
3. http://en.wikipedia.org/wiki/Idiopathic_orbital_inflammatory_disease


References

  1. 1.0 1.1 1.2 Weber AL, Romo LV, Sabates NR. Pseudotumor of the orbit: clinical, pathologic, and radiologic evaluation. Radiol Clin North Am 1999;37:151-168
  2. 2.0 2.1 2.2 2.3 Narla LD, Newman B, Spottswood SS, Narla S, Kolli R: Inflammatory Pseudotumor. Radiographics, online publication 2003;23:719-720
  3. Birch-Hirschfeld A. Zur Diagnostic and Pathologic der Orbital Tumoren. Bericht uber die Zusammenkunft der Deutschen Ophthalmologischen Gesellschaft 1905;32:127e35.
  4. Umiker WO, Iverson LC. Post inflammatory tumor of the lung: report of four cases simulating xanthoma, firboma, or plasma cell granuloma. J. Thorac Surg 1954;28:55-62
  5. Orbits, Eyelids, and Lacrimal System, AAO, BCSC Section 7, 2011-2012 pg. 59
  6. Yuen SJ, Rubin P. Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin N Am 2002;15:121-126
  7. 7.0 7.1 Blodi FC, Gass JDM. Inflammatory pseudotumor of the orbit. Br J Ophthalmol 1968;52:79-93
  8. 8.0 8.1 Blodi FC, Gass JDM. Inflammatory pseudotumor of the orbit. Tr Am Acad ophth and Otol 1967;71:303-322
  9. 9.0 9.1 9.2 Swamy BN, McCluskey P, Nemet A, Crouch R, Martin P, Benger R, Ghabriel R, Wakefield D. Idiopathic orbital inflammatory syndrome: Clinical features and treatment outcomes. Br J Ophthalmol 2007;91:1667-1670
  10. 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9 Ahn Yuen SJ, Rubin PAD. Idiopathic Orbital Inflammation Distribution, Clinical Features, and Treatment Outcome. Arch Ophthalmol. 2003;121:491-499
  11. 11.0 11.1 11.2 11.3 11.4 11.5 Espinoza GM. Orbital Inflammatory Pseudotumors: Etiology, Differential, Diagnosis, and Management. Curr Rheumatol Rep 2010;12:443-447
  12. Raskin EEM, McCormic SA, Maher EA. Granulomatous idiopathic orbital inflammation. Ophthal Plast Reconstr Surg 1995;11(2):131-135
  13. 13.0 13.1 13.2 Ophthalmic Pathology and Intraocular Tumors, AAO, BCSC Section 4, 2011-2012 pg. 231
  14. Reese AB. Tumors of the eye. New York: Harper; Row; 1951. p. 518
  15. Henderson JW, Farrow GM, editors. Orbital Tumors. Philadelphia: W.J. Saunders Co.; 1973. p.555
  16. Purcell JJ, Taulbee WA. Orbital myositis after upper respiratory tract infection. Arch Ophthalmol 1981;99:437-438
  17. Nieto JC, Kim N, Lucarelli MJ. Dacryoadenitis and orbital myositis associated with lyme disease. Arch Ophthalmol 2008;126:1165-1166
  18. Kawasaki A, Borruat FX. An unusual presentation of herpes zoster ophthalmicus: orbital myositis preceding vesicular eruption. Am J Ophthalmol 2003;136:574-575
  19. Volpe NJ, Shore JW. Orbital myositis associated with herpes zoster. Arch Ophthalmol 1991;109:471-472
  20. Wirostko E, Johnson L, Wirostko B. Chronic orbital inflammatory disease: parasitisation of orbital leucocytes by mollicute-like organisms. Br J Ophthalmol 1989;73:865-870
  21. Smith JW. Orbital pseudotumor and Crohn’s disease. Am J Gastroenterol 1992;87(3):405-406
  22. Serop S, Vianna RN, Claeys M, DE Laey JJ. Orbital myositis secondary to systemic lupus erythematosus. Acta Ophthalmol 1994;72:520-523
  23. Van de Mosselaer G, Deuren HV, Dewolf-Peeters C, et al. Pseudotumor orbitae and myasthenia gravis. Arch Ophthalmol 1980;98:1621-1622
  24. Woo TL, Francis IC, Wilcsek GA, Coroneo MT, McNab AA, Sullivan TJ. Australian orbital and adnexal Wegner’s granulomatosis. Ophthalmology. 2001;108: 1535-1543
  25. Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology 1997;104(3):402-408
  26. 26.0 26.1 26.2 Sobrin L, Kim E, Christen W et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125:895-900
  27. 27.0 27.1 Atabay C, Tyutyunikov A, Scalise D, et al. Serum antibodies reactive with eye muscle membrane antigens are detected in patients with nonspecific orbital inflammation. Ophthalmology. 1995;102:145-153
  28. Levine MR, Kaye L, Mair S, et al. Multifocal fibrosclerosis report of a case of bilateral idiopathic sclerosing pseudotumor and retroperitoneal fibrosis. Arch Ophthalmol. 1993;111:841-843
  29. 29.0 29.1 29.2 29.3 29.4 29.5 Rootman J, McCarthy M, White V, Harris G. Kennerdell: Idiopathic sclerosing inflammation of the orbit a distinct clinicopathologic entity. Ophthalmology. 1994;101:570-584
  30. McCarthy JM, White VA, Harris G, et al. Idiopathic sclerosing inflammation of the orbit: immunohistologic analysis and comparison with retroperitoneal fibrosis. Mod Pathol 1993;6:581-587
  31. Berry-Brincat A, Rose GE. Idiopathic orbital inflammation: a new dimension with the discovery of immunoglobulin G4-related disease. Curr Opin Opthalmol. 2012;23:415-419
  32. Mottow-Lippa L, Jakobiec FA, Smith M. Idiopathic inflammatory orbital pseudotumor in childhood II results of diagnostic tests and biopsies. Ophthalmology. 1981;88(6):565-574
  33. Wladis EJ, Iglesias BV, Gosselin EJ. Characterization of the Molecular Biologic Milieu of Idiopathic Orbital Inflammation. 2011;27:251-254
  34. Fries PD, Fohrman D, Char DH. Phorbol ester-induced orbital myositis. Arch Ophthalmo.l 1987;105:1273-1276
  35. Wladis EJ, Iglesias BV, Adam AP, Nazeer T, Gosselin EJ. Toll-Like Receptors in Idiopathic Orbital Inflammation. Ophthal Plast Reconstr Surg. 2012;28:273-276
  36. 36.0 36.1 Berger JW, Rubin PAD, Jakobiec FA. Pediatric orbital pseudotumor: case report and review of the literature. Int Ophthalmol Clin 1996;36:161-177
  37. 37.0 37.1 37.2 Ding ZX, Lip G, Chong V. Idiopathic orbital pseudotumor. Clinical Radiology 2011;66:886-892
  38. Kline LB, Hoyt WF. The Tolosa-Hunt syndrome. J Neurol Neurosurg Psychiatry 2001;71:577-582
  39. 39.0 39.1 Kapur R, Sepahdari AR, Mafee MF, et al. MR imaging of orbital inflammatory syndrome, orbital cellulitis, and orbital lymphoid lesions: the role of diffusion-weighted imaging. AJNR Am J Neuroradiol 2009;30:64-70
  40. Flanders Ae, Mafee MF, Rao VM, et al. The characteristics of orbital pseudotumor and other orbital inflammatory processes. J Comput Assist Tomogr 1989;13:40-47
  41. McKinney AM, Short J, Lucato L, et al. Inflammatory myofibroblastic tumor of the orbit with associated enhancement of the meninges and multiple cranial nerves. Am J Neuroradiol 2006;27:2217-2220
  42. Lee EJ, Jung Sl, Kim BS, et al. MR imaging of orbital inflammatory pseudotumors with extraorbital extension. Korean J Radiol 2005;6:82-88
  43. Clifton AG, Borgstein RL, Moseley IF, et al. Intracranial extension of orbital pseudotumor. Clin Radiol 1992;45:23-26
  44. 44.0 44.1 44.2 44.3 Jacobs D, Galetta S. Diagnosis and management of orbital pseudotumor. Curr Opin Ophthalmol 2002;13:347-351
  45. Agarwal A. Orbital pseudotumor: Diagnosis on fine needle aspiration cytology. J Cytol 2008;25:67-9
  46. Gupta S, Sood B, Gulati M, Takhtani D etl al. Orbital Mass Lesions: US-guided Fine-Needle Aspiration Biopsy – Experience in 37 Patients. Radiology 1999;213:568-572
  47. Dutton JJ. Orbit and lacrimal gland. In: Yanoff M, Duker JS, editors. Ophthalmology. Mosby, Inc., St. Louis, 2004, p.729-743
  48. Israele V, Nelson JD. Periorbital and orbital cellulitis. Ped Infect Dis J 1987;6:404-410
  49. 49.0 49.1 Mawn LA, Jordan DR, Donahue SP. Preseptal and Orbital Cellulitis. Ophthalmol Clin N Am 2000;13:633-41
  50. Lutt JR, Lim L, Phal PM, Rosenbaum JT. Orbital Inflammatory Disease. Semin Arthritis Rheum 2008;37:207-222
  51. Watkins LM, Carter KD, Nerad JA. Ocular Adnexal Lymphoma of the Extraocular Muscles: Case Series From the University of Iowa and Review of the Literature. Ophthal Plast Reconstr Surg. 2011;27:471-476
  52. Ahmad MS, Esmaeli B. Metastatic tumors of the orbit and ocular adnexa. Curr Opin Ophthalmol 2007;18:405-413
  53. Tarabishy AB, Schulte M, Papaliodis GN, Hoffman GS. Wegener’s Granulomatosis: Clinical Manifestations, Differential Diagnosis, and Management of Ocular and Systemic Disease. Surv Ophthalmol 2010;5:429-444
  54. Prabhakaran VC, Saeed P, Esmaeli B et al. Orbital and Adnexal Sarcoidosis. Arch Ophthalmol 2007;125(12):1657-1662
  55. Nageswaran S, Woods CR, Benjamin DK, Givner LB, Shetty AK. Orbital Cellulitis in Children. Pediatr Infect Dis J 2006;25:695-699
  56. Cockerham KP, Chan SS. Thyroid Eye Disease. Neurol Clin 2010;28:729-755
  57. Mannor GE, Rose GE, Moseley IF, et al. Outcome of orbital myositis: clinical features associated with recurrence. Ophthalmology 1997;104:409-414
  58. Green GA. Understanding NSAIDs: from aspiring to COX-2. Clinical cornerstone 2001;3:50-60
  59. 59.0 59.1 59.2 59.3 59.4 Mombaerts I, Schingmann RO, Goldschmeding R, et al. Are systemic corticosteroids useful in the management of orbital pseudotumors? Ophthalmol. 1996;103:521-528
  60. 60.0 60.1 60.2 60.3 60.4 60.5 Garrity JA, Kennerdell JS, Johnson BL, et al. Cyclophosphamide in the treatment of orbital vasculitis. Am J OphthalmoI 1986;102:97-103
  61. Bijlsma WR, Paridaens D, Kalmann R. Treatment of severe idiopathic orbital inflammation with intravenous methylprednisolone. Br J Ophthalmol 2011;95:1068-1071
  62. 62.0 62.1 62.2 Gordon LK. Orbital inflammatory disease: a diagnostic and therapeutic challenge. Eye 2006;20:1196-1206
  63. 63.0 63.1 63.2 Lanciano R, Fowble B, Sergott RC, et al. The results of radiotherapy for orbital pseudotumor. Int J Radiat Oncol Biol Phys 1990;18:407-411
  64. 64.0 64.1 Orcutt J, Garner A, Henk J, Wright J. Treatment of idiopathic inflammatory orbital pseudotumors by radiotherapy. Br J Ophthalmol 1983;67:570-574
  65. Smitt MC, Donaldson SS. Radiation therapy for benign disease of the orbit. Semin Rad Oncol 1999;9:179-189
  66. Kennerdell J, Johnson B, Deutsch M. Radiation treatment of orbital lymphoid hyperplasia. Ophthalmology 1979;86:942-947
  67. Sergott R, Glaser J, Charyulu K. Radiotherapy for idiopathic inflammatory orbital pseudotumor: indications and results. Arch Ophthalmol 1981;99:8536
  68. Snebold NG. Orbital pseudotumor syndromes. Curr Opin Ophthalmol 1997;8:41-44
  69. 69.0 69.1 69.2 Hemady R, Tauber J, Foster CS. Immunosupressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991;35:369-385
  70. Diaz-Llopez M, Menezo JL. Idiopathic inflammatory orbital pseudotumor and low-dose cyclosporine. Am J Ophthalmol 1989;107:547-548
  71. 71.0 71.1 Zacharopoulos IP, Papadaki T, Manor RS, Briscoe D. Treatment of idiopathic orbital inflammatory disease with cyclosporine-A: a case presentation. Semin Ophthalmol 2009 2009;24:260-261
  72. Gumus K, Mirza GE, Cavanagh HD, Karakucuk S. Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature. Eye Contact Lens 2009;35:275-278
  73. Bielory L, Frohman LP. Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991;98:1732-1736
  74. 74.0 74.1 74.2 74.3 74.4 74.5 Carruth BP, Wladis EJ. Inflammatory modulators and biologic agents in the treatment of idiopathic orbital inflammation. Curr Opin Ophthalmol 2012;23:420-426
  75. Buell C, Koo J: Long-term safety of mycophenolate mofetil and cyclosporine: a review. J Drugs Dermatol 2008;7:741-748
  76. 76.0 76.1 76.2 76.3 Chiu CS, Rubin PAD. Pharmacotherapies and Nonpharmacotherapies for Orbital Inflammatory Diseases. Int Ophthalmol Clin 2004;44(3):165-185
  77. Abeysiri P, Johnston NR, Molteno ACB. The Use of Topical Tacrolimus 0.1% Skin Ointment for Anterior Segment Conditions: A Case Series. Ophthalmology and Eye Diseases 2010;2:5-8
  78. Kymionis GD, Kankariya VP, Kontadakis GA. Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis. Cornea 2012;31(8):950-952
  79. 79.0 79.1 Winn BJ, Rootman J. Sclerosing Orbital Inflammation and Systemic Disease. Ophthal Plast Reconstr Surg 2012;28(2):107-118
  80. Kaushal K, Manchanda Y. Long -term safety and toxicity of azathioprine in patients with air-borne contact dermatitis. Indian J Dermatol Venereol Leprol 2001;67:75-7
  81. Attard NR, Karran P. UVA photosensitization of thiopurines and skin cancer in organ transplant recipients. Photochem Photobiol Sci. 2012;11(1):62-68
  82. 82.0 82.1 Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 2002;343(24):1750–1757
  83. 83.0 83.1 83.2 83.3 Paris GL, Waltuch GF, Egbert PR. Treatment of refractory orbital psuedotumours with pulsed chemotherapy. Ophthal Plast Reconstr Surg 1990;6:96-101
  84. 84.0 84.1 Eagle K, King A, Fisher C, Souhami R. Cyclophosphamide induced remission in relapsed, progressive idiopathic orbital inflammation (PSeudotumor). Clin Oncol 1995;7:402-404
  85. 85.0 85.1 Lawson M, Vasilaras A, De Vries A, Mactaggart P, Nicol D. Urological implication of cyclophosphamide and ifosfamide. Scand J Urol Nephrol 2008;42(4):309-317
  86. 86.0 86.1 Marino A, Wason WM. Successful Treatment of Idiopathic Orbital Inflammatory Disease with Leflunomide: A Case Report. Southern Medical Journal 2009;102:1085-1087
  87. Kaltwasser JP. Leflunomide in psoriatic arthritis. Autoimmun Rev 2007;6:511-514
  88. Jaimes-Hernandez J, Melendez-Mercado CI, Mendoza-Fuentes A, Aranda-Pereira P, Castaneda-Hernandez G. Efficacy of leflunomide 100 mg weekly compared to low dose methotrexate in patient with active rheumatoid arthritis. Double blind, randomized clinical trial. Rheumatogia Clinica 2012;8(5):243-249
  89. van Riel PLCM, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol 2004;71:21-24
  90. 90.0 90.1 90.2 Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001;85:1220-1224
  91. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99:1419-1423
  92. Daniel, E, Thorne, JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. American Journal of Ophthalmology 2010;149(3):423-432
  93. 93.0 93.1 Hatton MP, Rubin PAD, Foster SC. Successful Treatment of idiopathic Orbital Inflammation With Mycophenolate Mofetil. Am J Ophthalmol 2005;140:916-918
  94. 94.0 94.1 94.2 Patel AK, Hoch S, Shindler KS. Mycophenolate mofetil treatment of steroid-resistant idiopathic sclerosing orbital inflammation. Clinical and Experimental Ophthalmology 2011;39(9):912-913
  95. Moss HE, Mejico LJ, De La Roza G, Coyne TM, Galetta SL, Liu GT. IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil. Journal of the Neurological Sciences 2012;318(1-2):31-35
  96. Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33:2162–6
  97. 97.0 97.1 97.2 97.3 Kremer JM, Genant HK, Moreland LW, et al. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. Ann Intern Med 2006;144:865-876
  98. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-TNFalpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010;62:821-825
  99. Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis - A case report. Journal of Rheumatology 2008;35(9):1897-1898
  100. Yue C, You X, Zhao L et al. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010;30(12):1553–1557
  101. 101.0 101.1 Rudwaleit M, Claudepierre P, Wordsworth P et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36(4):801–808
  102. van den Bosch F, Manger B, Goupille P et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions. Ann Rheum Dis 2010;69(2):394–399
  103. Takase K, Ohno S, Ideguchi H et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behc¸et disease-related uveitis. Rheumatol Int 201131(2):243–245
  104. Biester S, Deuter C, Michels H et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91(3):319–324
  105. Adams AB, Kazim M, Lehman TJA. Treatment of Orbital Myositis with Adalimumab. J Rheumatol 2005;32:1374-1375
  106. Khanna D, McMahon M, Furst DE. Safety of tumor necrosis factor-alpha antagonists. Drug Saf 2004;27:307-324
  107. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. Journal Of Dermatological Treatment 2004;15(5):280-294
  108. Chung JH, Van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. Journal of the Neurological Sciences, 2006;244(1-2):133-136
  109. Michalova, K, Lim L. Biologic agents in the management of inflammatory eye diseases. Current Allergy and Asthma Reports 2008;8(4):339-347
  110. 110.0 110.1 Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999;96:7462–7466
  111. 111.0 111.1 Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003;110(4):786-789
  112. 112.0 112.1 Garcia-Pous M, Hernandez-Garfella ML, Diaz-Llopis M. Treatment of chronic orbital myositis with daclizumab. Can J Ophthalmol 2007;42(1):156-157
  113. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. The Lancet 2004;363(9410):675-681
  114. Philip J, Mease MD, Bernard S, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial The Lancet 2000;356(9227):385-390
  115. Brandt J, Kharioouzov A, Listing J, et al. Six-Month Results of a Double-Blind, Placebo-Controlled Trial of Etancercept Treatment in Patients With Active Ankylosing Spondylitis. Arthritis & Rheumatism 2003;48(6):1667-1675
  116. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062-1147
  117. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005;352:351-361.
  118. Paridaens D. van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves’ ophthalmopathy: A pilot study. Eye 2005;19(12):1286-1289
  119. Taban M, Dupps WJ, Mandell B, et al. Etanercept (Enbrel)-Associated Inflammatory Eye Disease: Case Report and Review of the Literature. Ocular Immunology and Inflammation 2006;14:145-150
  120. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004;31(7):1362-1368
  121. Capella MJ, Foster CS Long-term efficacy and safety of infliximab in the treatment of Behçet's disease. Ocular Immunology and Inflammation 2012;20(3):198-202
  122. Garrity JA, Coleman AW, Matteson EL, et al. Treatment of Recalcitrant Idiopathic Orbital Inflammation (Chronic Orbital Myositis) With Infliximab. Am J Ophthalmol 2004;138:925-930
  123. Miguel T, Abad S, Badelon I, Vignal C, et al. Successful treatment of idiopathic orbital inflammation with infliximab: An alternative to conventional steroid-sparing agents. Ophthal Plast Reconstr Surg 2008;24(5):415-417
  124. Sahlin S, Lignell B, Williams M, et al. Treatment of idiopathic sclerosing inflammation of the orbit (myositis) with infliximab. Acta Ophthalmol 2009;87:906-908
  125. Wilson MW, Shergy WJ, Haik BG. Infliximab in the Treatment of Recalcitrant Idiopathic Orbital Inflammation. 2004;20(5):381-399
  126. 126.0 126.1 Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722–729
  127. 127.0 127.1 Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167–2179
  128. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002;20(Suppl 28):S152–S157
  129. Kremer JM. Rational use of new and existing disease modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695–706
  130. On A, Hirschbien M, Williams H, Karesh J. CyberKnife radiosurgery and rituximab in the successful management of sclerosing idiopathic orbital inflammatory disease. Ophthalm Plas Reconstr Surg 2006;22:395-397
  131. Schafranski. Idiopathic orbital inflammatory disease successfully treated with rituximab. Clin Rheumatol 2009;28:225-226
  132. Ibrahim I, Barton A, Ibrahim A, Ho P. Idiopathic Orbital Inflammation Successfully treated Using Rituximab in a Patient with Rheumatoid Arthritis. J Rheumatol 2012;39(7):1485-1486
  133. Esmaeli B, Murray JL, Ahmadi MA, et al. Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit. Arch Ophthalmol 2002;120:1225–7
  134. Yokota S, Imagawa T, Mori M, et al. Efficacu and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006
  135. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized antiinterleuken-6 receptor antibody: a multicenter, double blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-1769
  136. de la Maza MS, Molina N, Gonzalez-Gonzalez, et al. Scleritis Therapy. Ophthalmology 2012;119:51-58
  137. Tappeiner C, Heinz C, Ganser G. Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis? J Rheumatol 2012;39(6):1294-1295
  138. Venkiteshwaran A. Tocilizumab. MAbs 2009;1:432-8
  139. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609--32
  140. 140.0 140.1 140.2 Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin and Exper Ophthalmol 2006;34:365-374
  141. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484–486
  142. Rosenbaum JT, George RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999;127:545–549.
  143. Shambal S, Lindner A, Zierz S. Successful treatment of orbital myositis with intravenous immunoglobulins. Muscle Nerve. 1998;21:1359-1360
  144. Symon Z, Schneebaum N, Eyal A, et al. Successful Intravenous Immunoglobulin Therapy for Resistant Inflammatory Pseudotumor of the Orbit. Thyroid 2005;14(4):398-399
  145. Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, Fallahi. Intravenous immunoglobulin versus corticosteroid in treatment of Graves’ ophthalmopathy. Thyroid 1997;7:579–585.
  146. 146.0 146.1 Pemberton JD, Fay A. Idiopathic Sclerosing Orbital Inflammation: A Review of Demographics, Clinical Presentation, Imaging, Pathology, Treatment, and Outcome. Ophthal Plast Reconstr Surg 2012;28:79-83

Original article contributed by: Rao Chundury, MD MBA, Anupama Chundury, MS, Gabriella Espinoza, MD
{| cellspacing="5"

|-!align="right" |Lead Editors: |add |- !align="right" |Contributing Editors: |add |-

|}


Personal tools